This may seem like a bit of a nothing announcement to some, but I think this is a massive telegraphing of what is now to come.
This is the key paragraph for me. Clearly discussions have been going on with many parties, they have realized many of those parties are European based, the parties have liked what they have seen with the EVPS technology, and there is a need for Exopharm to get closer to those potential partners in order to get into partnering deals and work with them.
Two of the largest pharma companies in the world have Head Offices in Switzerland, Roche and Novartis, and Sanofi is in France and Bayer is in Germany.
Looks like the first two steps on the stairway to (financial ) heaven have been made. 71c needs taken out first, but I have some lofty targets on this over 24 months and happy to sit and accumulate.
With COVID bringing such a massive focus to healthcare, drug delivery, research etc, this sector will see investment and funds flow greater than ever and this should benefit those at the cutting edge like EX1.
